# A Study for Participants With Advanced Cancer

> **NCT01214629** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 54 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** LY2523355
- **DRUG:** LY2523355
- **DRUG:** pegfilgrastim

## Key facts

- **NCT ID:** NCT01214629
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214629, "A Study for Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01214629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*